(MENAFN- Newsfile Corp) Twist Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Twist To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - November 24, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience Corporation ('Twist' or the 'Company') (NASDAQ: TWST).
If you suffered losses exceeding $50,000 investing in Twist stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . You may also click here for additional information: .
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Twist is the subject of a research report published on November 15, 2022, by Scorpion Capital. The report describes the Company as 'a cash-burning inferno that is not a going concern, operating a ponzi-like scheme that will end in bankruptcy.'
Based on this report, shares of Twist fell by more than 18% in morning trading on the same day.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.